Caris introduces Caris Assure liquid biopsy assay
July 2022—Caris Life Sciences introduced its Caris Assure liquid biopsy assay at the American Society of Clinical Oncology annual meeting in June.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
BioMérieux Chikungunya dx tests get CE mark
July 2022—BioMérieux announced the CE marking of its Vidas Anti-Chikungunya IgM and Anti-Chikungunya IgG tests to diagnose Chikungunya virus infection. The tests can detect infection during the acute phase and into the chronic phase and run on the company’s Vidas immunoassay instruments.
FDA clears Scopio Labs hematology digital cell morphology platform
July 2022—Scopio Labs received FDA 510(k) clearance for its X100HT hematology digital cell morphology platform with peripheral blood smear review.
GenScript, Euroimmun enter distribution agreement
July 2022—GenScript USA has reached an agreement with Euroimmun US, a PerkinElmer company, for the distribution of the GenScript cPass SARS-CoV-2 Neutralization Antibody Detection Kit in the United States and Canada.
Creative Dx releases Nipah virus mAb pairs
July 2022—Creative Diagnostics has released a range of Nipah virus recombinant antigens and monoclonal antibody pairs. The monoclonal antibodies can be used as a pair in sandwich ELISA with the recombinant protein or in capture IgM assays. The products are specific to Nipah virus, with no cross-reaction with dengue, Zika, and chikungunya envelope proteins.
Bio-Rad releases three StarBright ultraviolet dyes
July 2022—Bio-Rad Laboratories introduced three StarBright dyes designed for use with a 355 nanometer UV laser in flow cytometry applications. StarBright UltraViolet 510, 665, and 795 dyes offer exceptional brightness, the company says, with narrow excitation and emission profiles for precise resolution.
BD launches infectious disease molecular Dx platform
July 2022—BD announced the U.S. launch of its fully automated, high-throughput infectious disease molecular diagnostics platform, the BD COR MX. The 510(k)-cleared instrument is an analytic option for the modular and scalable BD COR system.
Streck introduces viral extraction kit
July 2022—Streck, in partnership with Ceres Nanosciences, announced the availability of its viral extraction kit for clinical samples containing SARS-CoV-2 and influenza A.
Illumina introduces pan-cancer CDx
July 2022—Illumina announced that a companion diagnostic indication has been added to its CE-marked in vitro diagnostic TruSight Oncology Comprehensive (EU) test. The CDx pan-cancer indication will allow identification of cancer patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase gene fusions including NTRK1, NTRK2, or NTRK3 and who may benefit from targeted therapy with Bayer’s Vitrakvi (larotrectinib), a genomically matched treatment.
Proscia, Hamamatsu digital pathology collaboration
May 2022—Proscia and Hamamatsu Photonics are collaborating to accelerate the adoption of digital pathology. The agreement aims to increase the availability of the companies’ best-of-breed solution, which combines Proscia’s Concentriq platform and Hamamatsu’s NanoZoomer series of whole slide scanners, to laboratories. Users of Hamamatsu’s scanners can integrate their images and all other data into an open ecosystem centered around Concentriq. Under the agreement, customers will receive support with implementation.